Classes
DEA Class; Rx
Common Brand Names; Rescriptor
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)s
Description
Non-nucleoside reverse transcriptase inhibitor (NNRTI)
Used with other antiretroviral drugs to treat HIV infection in patients 16 years and older
May cause drug-induced rashes
Indications
Indicated for the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.
Contraindications
Unplanned antiretroviral therapy interruption may be necessary in specific situations, such as serious drug toxicity, intercurrent illness or surgery precluding oral intake (e.g., gastroenteritis or pancreatitis), severe hyperemesis gravidarum unresponsive to antiemetics, or drug non-availability.
Adverse Effects
- angioedema
- Stevens-Johnson syndrome
- erythema multiforme
- hepatic failure
- hemolytic anemia
- rhabdomyolysis
- renal failure
- vasculitis
- GI bleeding
- cardiomyopathy
- pancreatitis
- muscle paralysis
- laryngospasm
- pancytopenia
- hyperkalemia
- epididymitis
Pregnancy and Lactation
Antiretroviral prophylaxis should be provided to all women during pregnancy, regardless of HIV RNA concentrations or CD4 cell count.
Maximum Dosage
1200 mg/day PO.
1200 mg/day PO.
>= 16 years: 1200 mg/day PO.
< 16 years: Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Delavirdine mesylate
Rescriptor Oral Tab: 100mg, 200mg
